On June 2, 2022 Sarah Cannon Research Institute reported that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago and online from June 3-7, 2022 (Press release, Sarah Cannon Research Institute, JUN 2, 2022, View Source [SID1234615465]). Experts from across Sarah Cannon Research Institute’s network will join oncology leaders from around the globe to discuss the latest research findings that are accelerating progress in the fight against cancer. As a leader in drug development, Sarah Cannon Research Institute is presenting data from 75 early-phase studies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Collaboration is essential to how we accelerate progress in the fight against cancer, and we look forward to coming together with our colleagues in Chicago to discuss the latest advances in oncology research," said Howard A. "Skip" Burris III, MD, FACP, FACSO, President, Clinical Operations & Chief Medical Officer, Sarah Cannon Research Institute. "With the variety of novel molecularly-targeted agents, immunotherapies, and cellular therapies in development, we are seeing a remarkable number of possibilities to truly transform care and personalize treatments for patients."
Presentations will cover a wide range of topics including how targeted agents and immunotherapies are performing in an array of disease settings, how molecular profiling is expanding access to clinical trials, and how researchers are advancing clinical research despite pressures in a post-pandemic environment.
Below are several highlighted presentations that Sarah Cannon principal investigators will lead during the Annual Meeting:
Gerald Falchook, MD, MS, Director, Drug Development, Sarah Cannon Research Institute at HealthONE, will deliver "Phase 1 Trial of TIM-3 Inhibitor Cobolimab Monotherapy and in Combination with PD-1 Inhibitors Nivolumab or Dostarlimab (AMBER)" in an oral presentation on June 4 from 1:15-4:15 p.m. CDT (2:27 p.m. CDT) in Hall B1.
Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, will give two oral presentations – "Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (pts) with HER2-Positive (HER2+) Unresectable and/or Metastatic Breast Cancer (mBC): Safety Follow-Up of the Randomized, Phase 3 Study DESTINY-Breast03" on June 4 from 1:15-4:15 p.m. CDT (1:15 p.m. CDT) in Hall D1 and "Phase I, Two-Part, Multicenter, First-In-Human (FIH) Study of DS-6000a in Subjects with Advanced Renal Cell Carcinoma (RCC) and Ovarian Tumors (OVC)" on June 7 from 9:45 a.m. – 12:45 p.m. CDT (10:09 a.m. CDT) in S406.
Melissa Johnson, MD, Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, will present "Resistance to KRAS Inhibition and Future Combinations" in the Education Session, Development of Novel Inhibitors of the RAS Pathway, on June 7 from 8-9:15 a.m. CDT in S406. Dr. Johnson will also present "Dose Escalation of a Phase 1b/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (pts) with Metastatic Solid Tumors" in an oral presentation on June 4 from 1:15-4:15 p.m. CDT (1:51 p.m. CDT) in Hall B1.
Andrew McKenzie, PhD, Vice President, Personalized Medicine, Sarah Cannon Research Institute; Scientific Director, Genospace, will present "Expanding Access to Clinical Trials Through Molecular Profiling Review and Telehealth Consultations" during the Education Session, Rethinking Cancer Clinical Trial Conduct With Telemedicine, on June 6 from 4:45-6 p.m. CDT in S504.
Jeremy Pantin, MD, Senior Investigator, Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial, will chair the Clinical Science Symposium, Beating Bad Blood: The Power of Immunotherapy in Hematologic Malignancies, as well as discuss "Refining the CAR-T’s Engine: How to Improve CD19-Directed CAR-T Performance" on June 6 from 8-9:30 a.m. CDT in S100bc.
David Spigel, MD, Chief Scientific Officer, Sarah Cannon Research Institute, is a speaker and panelist on the Education Session, The Business of Clinical Trials: The Impact of Funds Flow and the Shrinking Workforce on Trial Development, on June 5 from 8-9:15 a.m. CDT in S102.
Abstracts and presentations with Sarah Cannon experts as first authors will be presented by:
Dr. Howard Burris
Dr. Gerald Falchook
Lucio Gordan, MD, Chief Medical Officer, Sarah Cannon Research Institute at Florida Cancer Specialists
Dr. Erika Hamilton
Marilyn (Holt) Hammer, PhD, Program Specialist, Personalized Medicine, Sarah Cannon Research Institute
Lowell Hart, MD, FACP, Scientific Director, Clinical Research, Sarah Cannon Research Institute at Florida Cancer Specialists
Shekeab Jauhari, MD, Associate Director, Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists – Lake Mary
Dr. Melissa Johnson
William Kevin Kelly, DO, Senior Investigator, Drug Development, Sarah Cannon Research Institute at Sidney Kimmel Cancer Center
Meredith McKean, MD, MPH, Director, Melanoma & Skin Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology
Dr. Andrew McKenzie (Chair)
Kathleen Moore, MD, Director, Drug Development, Sarah Cannon Research Institute at the Stephenson Cancer Center
Manish Patel, MD, Director, Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists – Sarasota
Meredith Pelster, MD, MSCI, Assistant Director, Gastrointestinal Research, Sarah Cannon Research Institute at Tennessee Oncology
Cesar Augusto Perez, MD, Director, Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists – Lake Nona
Russell Schilder, MD, Director, Drug Development, Sarah Cannon Research Institute at Sidney Kimmel Cancer Center
Emma Sturgill, PhD, Senior Program Specialist, Personalized Medicine, Sarah Cannon Research Institute
Susanna Ulahannan, MD, MMed, Associate Director, Phase 1 Program, Sarah Cannon Research Institute at The Stephenson Cancer Center (Co-Chair)